Abstract Demyelinating Charcot-Marie-Tooth disease (CMT) and chronic inflammatory demyelinating polyneuropathy (CIDP) are both demyelinating polyneuropathies. The differences in nerve enlargement degree and pattern at multiple evaluation sites/levels are not well known. We investigated the differences in nerve enlargement degree and the distribution pattern of nerve enlargement in patients with demyelinating CMT and CIDP, and verified the appropriate combination of sites/levels to differentiate between these diseases. Ten patients (aged 23-84 years, three females) with demyelinating CMT and 16 patients (aged 30-85 years, five females) with CIDP were evaluated in this study. The nerve sizes were measured at 24 predetermined sites/levels from the median and ulnar nerves and the cervical nerve roots (CNR) using ultrasonography. The evaluation sites/levels were classified into three regions: distal, intermediate and cervical. The number of sites/levels that exhibited nerve enlargement (enlargement site number, ESN) in each region was determined from the 24 sites/levels and from the selected eight screening sites/levels, respectively. The cross-sectional areas of the peripheral nerves were markedly larger at all evaluation sites in patients with demyelinating CMT than in patients with CIDP (p \ 0.01). However, the nerve sizes of CNR were not significantly different between patients with either disease. When we evaluated ESN of four selected sites for screening from the intermediate region, the sensitivity and specificity to distinguish between demyelinating CMT and CIDP were 0.90 and 0.94, respectively, with the cut-off value set at four. Nerve ultrasonography is useful to detect nerve enlargement and can clarify morphological differences in nerves between patients with demyelinating CMT and CIDP.
Introduction
The differential diagnosis of demyelinating CharcotMarie-Tooth disease (CMT) from chronic inflammatory demyelinating polyneuropathy (CIDP) is generally based on a clinical history that includes a family history, physical findings, nerve conduction studies (NCS) and genetic tests [1, 2] . However, patients with demyelinating CMT and CIDP can present with overlapping clinical symptoms and electrodiagnostic testing abnormalities [3, 4] , and the detection rate for gene mutations is not as high (32-49 %) in patients with demyelinating CMT [5] . Therefore, it is not always easy to differentiate between these diseases.
Peripheral nerve enlargement has been reported in patients with demyelinating CMT or CIDP based on magnetic resonance imaging (MRI) [6] [7] [8] [9] [10] [11] [12] and ultrasonography (US) [13] [14] [15] [16] . In the consensus guideline on the definition of CIDP announced by the European Federation of Neurological Societies/Peripheral Nerve Society diagnostic criteria (EFNS/PNS) [17] , MRI evaluation of the spinal roots was recommended to assist with the diagnosis. Additionally, this guideline proposed hereditary demyelinating neuropathy, such as CMT, which exhibits nerve enlargement, as an exclusion criterion. Two comparative studies have demonstrated differences in nerve enlargement between CMT and CIDP using MRI or US [12, 16] . However, in those studies, the nerve sizes were evaluated at a few predetermined sites. It is still not clear whether the distribution patterns of the peripheral nerve enlargement associated with these diseases are similar. Therefore, evaluating peripheral nerve enlargement at limited predetermined sites may not be suitable.
The aim of the present study was to investigate differences in the degree of nerve enlargement and the distribution pattern of nerve enlargement at multiple sites/levels along the median and ulnar nerves and among the cervical nerve roots (CNR) in patients with demyelinating CMT and CIDP. Furthermore, we verified the appropriate combination of evaluation sites/levels to differentiate between these diseases.
Patients and methods

Patients
In the present study, which was approved by the ethics committee of Hiroshima University Hospital, we examined ten patients (aged 23-84 years, three females and seven males) with demyelinating CMT and 16 patients (aged 30-85 years, five females and 11 males) with CIDP who had undergone nerve US in our hospital from June 2007 to August 2012. The diagnostic approach to demyelinating CMT included the following five components: clinical phenotype, including the inheritance pattern; physical findings; electrophysiological examination; molecular analysis; and nerve biopsy [1] . All CIDP patients were classified as definite and typical CIDP according to the EFNS/PNS guideline [17] . The Hughes grade was used as the disability grade scale [18] . The maximum value of cerebrospinal fluid protein was investigated from the past measurements for each patient.
Methods
The ultrasound examinations were performed using an SSA-770A imaging system (Toshiba, Tokyo, Japan) with a 7-14 MHz linear-array transducer. All the participants were examined in the supine position with the arm supinated and abducted at body level. The cross-sectional area (CSA) was measured by tracing the nerve just inside its hyperechoic rim, which corresponds to the epineurium, as reported previously [19] . The CSA was measured bilaterally along the median and ulnar nerves. The CSA for each nerve was evaluated at predetermined sites [19] . Briefly, five sites along the median nerve were evaluated: the distal wrist crease at the pisiform bone level (MedWrist), the distal forearm (MedDist), the proximal forearm (MedProx), the antecubital fossa (MedElbow) and the mid-humerus (MedArm). Five sites along the ulnar nerve were evaluated: the distal wrist crease (UlnGuyon), the distal forearm (UlnDist), the arterial split (UlnProx), the tip of the medial epicondyle (UlnElbow) and the mid-humerus (UlnArm). Additionally, the diameters of the bilateral fifth (C5) and sixth (C6) CNR were measured. The root diameters were measured between the inner surfaces of the hyperechoic rims at three points within 2 cm distal to the transverse process [19] . The average of those values was calculated for each nerve root. CNR hypertrophy score was calculated as the sum of the diameters of the bilateral C5 and C6 nerve roots [14] . The minimal unit of CSA and CNR diameter was 1 mm 2 and 0.1 mm, respectively. For example, Fig. 1 illustrates the ultrasonographic appearance of the nerve at the screening sites/level in a patient with CMT1A and a patient with CIDP. Two investigators (TS or KO) obtained the ultrasonographic images for all patients with the clinical information. Nerve enlargement at each evaluation site was defined as a nerve size greater than or equal to the mean reference values plus two standard deviations according to gender [19] .
To investigate the distribution pattern of nerve enlargement, the evaluation sites/levels were classified into three regions: distal, intermediate and cervical (Fig. 2) . The distal region for the overall evaluation was defined as the bilateral MedWrist and UlnGuyon sites. The intermediate region for the overall evaluation was defined as the bilateral MedDist, MedProx, MedElbow, MedArm, UlnDist, UlnProx, UlnElbow and UlnArm sites. The cervical region for the overall evaluation was defined as the bilateral C5 and C6 nerve root levels. To evaluate distribution pattern of nerve enlargement among the regions (distal, intermediate and cervical), we defined nerve enlargement for each region when enlargement was detected at at least one evaluation site/level.
The number of sites/levels that exhibited nerve enlargement [enlargement site number (ESN)] in each region was determined (Fig. 2) . We proposed four evaluation sites/level, MedWrist, MedArm, UlnProx and C5, for screening peripheral nerve enlargement in our previous study [19] . These sites/level were also classified in each region. For screening, the bilateral MedWrist sites were classified in the distal region, the bilateral MedArm and UlnProx sites in the intermediate region and the bilateral C5 nerve root level in the cervical region.
Statistical analysis
The data were expressed as the median (minimum, maximum) for continuous variables. Statistical analysis was performed with IBM SPSS Statistics, version 19 (Chicago, IL). The Mann-Whitney U test was used for continuous 
Fisher's exact test was also used to evaluate the frequency of patients who showed specific distribution pattern of nerve enlargement between demyelinating CMT and CIDP. The area under the receiver operating characteristic curve (AUC) of the ESN in each region for overall evaluation or screening was calculated for differentiating demyelinating CMT from CIDP.
Results
The clinical data for patients with demyelinating CMT and CIDP are summarized in Table 1 . No significant differences were noted with respect to age, gender, height, weight or body mass index between patients with CMT and CIDP. Diabetes mellitus and malignancy tended to coexist more often in patients with CIDP, but this association was not significantly different from patients with demyelinating CMT. Demyelinating CMT was diagnosed based on the following criteria: six patients with CMT1A confirmed by the duplication of the peripheral myelin protein 22 gene, three patients with a family history of the disease and one patient with childhood onset and a very slow progressive time course. No patients with CIDP had a family history of demyelinating CMT.
In patients with demyelinating CMT, the nerve sizes were significantly larger at all evaluation sites along the peripheral nerves than in patients with CIDP (Fig. 3) . In contrast, the nerve sizes among CNR and the CNR hypertrophy score were not significantly different between patients with either disease. The ESN for overall evaluation (ESN-A), ESN in the intermediate region for overall evaluation (ESNit-A) and ESN in the intermediate region for screening (ESNit-S) were greater in patients with demyelinating CMT than in patients with CIDP ( Fig. 4 ; p \ 0.001 for ESN-A, ESNit-A and ESNit-S). In patients with demyelinating CMT, no nerve sizes at any site/level were associated with the patient's age at testing with nerve US (data not shown; combined data from the bilateral side).
The number of demyelinating CMT patients with nerve enlargement in every region (distal, intermediate and cervical) was more frequent than in CIDP patients (Table 2 ; p \ 0.05). Furthermore, in the intermediate region, nerve enlargement existed in all demyelinating CMT patients. Five of the six patients with genetically confirmed CMT1A had nerve enlargement in every region. In addition, two of the 16 patients (12.5 %) with CIDP had no nerve enlargement in any region.
The receiver operating characteristic curves of the ESN for each region are depicted in Fig. 5 . The AUC of ESNit-A was 0.96 [p \ 0.001; 95 % confidence interval (CI) 0.89-1.00] and the AUC of ESNit-S was 0.93 (p \ 0.001; 95 % CI 0.83-1.00). In overall evaluation, the highest sensitivity and specificity of ESNit-A were 0.90 and 0.94, respectively (cut-off value for ESNit-A, 11; overall accuracy 92.3 %). In screening, the highest sensitivity and specificity of ESNit-S were also 0.90 and 0.94, respectively (cut-off value for ESNit-S, 4; overall accuracy 92.3 %). In patients with demyelinating CMT, the minimum score was eight for ESNit-A and two for ESNit-S.
Discussion
Evaluating nerve sizes in the intermediate region is suitable to differentiate demyelinating CMT from CIDP. ESNit-S is sufficient for screening to differentiate demyelinating CMT from CIDP to reduce the examination time. In the diagnostic criteria for CIDP from the EFNS/PNS guideline, enlargement of the CNR detected with MRI is included as a supportive criterion [17] . Among the CNR, however, nerve enlargement occurred to the same degree in patients with demyelinating CMT and CIDP in our study. It is difficult to distinguish between these diseases based on the CNR sizes. The CSAs of the peripheral nerves were significantly larger at all evaluation sites in CMT patients than in CIDP patients. CSA evaluation along the median and ulnar nerves may lead to a more certain diagnosis of demyelinating CMT.
The differentiation points were investigated between demyelinating CMT and CIDP in our study. NCS plays a pivotal role in the diagnosis of demyelinating neuropathy [20] . Demyelinating CMT is characterized by uniform conduction slowing in all nerve segments [20, 21] . However, not all studies have confirmed uniform conduction slowing in patients with demyelinating CMT [22] .
Furthermore, in our study, all patients with demyelinating CMT satisfied the electrodiagnostic criteria of CIDP from the EFNS/PNS guideline. Therefore, NCS cannot always differentiate demyelinating CMT from CIDP. In view of the age of onset, four of the six patients with CMT1A in our study had a late onset of older than 65 years old. Therefore, hereditary demyelinating neuropathy should not be excluded by the age of onset. Additionally, genetic tests can differentiate between these diseases if known gene mutations are found. However, there are still unknown causes in patients with CMT [5] . Furthermore, patients may refuse to take genetic tests for ethical reasons. In such a circumstance, nerve US will be a useful tool for the differentiation between the two diseases, and the results of nerve US play a complementary role in the results of NCS.
MRI is a noninvasive method to evaluate nerve size. Gadolinium enhancement of the CNR can be detected with MRI in patients with CIDP [8] . However, regarding the Table 1 quantitative evaluation of nerve size using MRI, a previous study reported nerve size reference values of the CNR from a small number of normal subjects, and the reliability of these reference values has not been verified [10] . In our study, the quantitative evaluation of nerve size was performed using nerve US through comparison with reference values from a larger number of normal subjects; these reference values had previously been verified for reliability [19] . Furthermore, nerve US can allow us to easily perform a continuous observation of the nerves from the wrist to the arm and evaluate the nerve sizes from multiple sites in one examination. Fig. 4 Evaluation of nerve enlargement using the enlargement site number in patients with demyelinating CMT and CIDP. The abbreviations used in Fig. 4 are provided in Fig. 2 and Table 1 Our study has limitations. First, this study was investigated in a single research facility, and the number of cases was limited. Therefore, further study including more cases in multiple research facilities is needed. Second, no genetic confirmation was completed in four patients with demyelinating CMT or in any of the patients with CIDP. Finally, our results were based on a cross-sectional design. Therefore, a follow-up survey is needed to determine the degree of nerve size change in patients with demyelinating CMT and CIDP.
In conclusion, nerve sizes along the median and ulnar nerves were significantly larger at all evaluation sites in patients with demyelinating CMT than in patients with CIDP. Nerve US is useful for identifying the marked enlargement of peripheral nerves in patients with demyelinating CMT. Screening to evaluate ESNit-S is a candidate for distinguishing between demyelinating CMT and CIDP. The other abbreviations used in Table 2 are provided in Table 1 Fig . 5 The receiver operating characteristic curve for the enlargement site number in each region to differentiate demyelinating CMT from CIDP. The red line corresponds to each region for the overall evaluation. The blue line corresponds to each region for the screening. AUC area under the receiver operating characteristic curve
